中国药物警戒 ›› 2025, Vol. 22 ›› Issue (6): 686-688.
DOI: 10.19803/j.1672-8629.20250120

• 安全与合理用药 • 上一篇    下一篇

注射用头孢哌酮舒巴坦钠致血小板减少1例分析

王浩1, 马劲夫2, 马瑞3, 李晓刚2, 赵强3#, 张弦3*   

  1. 1国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100076;
    2中国人民解放军第三〇五医院重症监护室,北京 100017;
    3中国人民解放军第三〇五医院药局,北京 100017
  • 收稿日期:2025-02-27 发布日期:2025-06-18
  • 通讯作者: *张弦,女,主管药师,临床药学与药事管理。E-mail: 65840582@qq.com;#为共同通信作者。
  • 作者简介:王浩,男,在读博士,老年医学。
  • 基金资助:
    国家科技重大专项重大新药创制（2019ZX09201005）

One Case of Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium for Injection

WANG Hao1, MA Jinfu2, MA Rui3, LI Xiaogang2, ZHAO Qiang3#, ZHANG Xian3*   

  1. 1Center for Drug Reevaluation NMPA/NMPA, Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100076, China;
    2Intensive Care Unit, Hospital 305 of PLA, Beijing 100017, China;
    3Department of Pharmacy, Hospital 305 of PLA, Beijing 100017, China
  • Received:2025-02-27 Published:2025-06-18

PDF (PC)

64

摘要： 目的 探讨头孢哌酮舒巴坦钠致血小板减少的用药特点,为安全使用该药和防治药品不良反应提供参考。方法 分析注射用头孢哌酮舒巴坦钠引起血小板减少的病例,通过关联性评价和查询文献对头孢哌酮舒巴坦钠致血小板减少的不良反应及发病机制进行分析,并提出防治措施。结果 经查阅药品说明书和文献,分析用药时间,排除其他联用药,考虑为头孢哌酮舒巴坦钠致的不良反应,患者经停用该药和支持治疗后,血小板逐渐恢复正常。结论 关注头孢哌酮舒巴坦等抗生素致血小板减少的风险,对高龄、重症、用药疗程较长和肝肾功不全等高风险人群用药期间加强监测血小板,保障患者的用药安全。

关键词: 头孢哌酮舒巴坦钠, 血小板减少, 药品不良反应, 抗生素, 合理用药

Abstract: Objective To study the characteristics of thrombocytopenia induced by cefoperazone sulbactam sodium, and to provide a reference for safe clinical use and management of adverse drug reactions. Methods One case of thrombocytopenia caused by cefoperazone sulbactam sodium for injection was studied. The adverse reactions and pathogenesis of thrombocytopenia caused by cefoperazone sulbactam sodium were analyzed via correlation evaluation and literature review before ways of prevention and treatment were recommended. Results After the drug instructions and literature were reviewed, and the time of administration was analyzed, other combination drugs were excluded. Cefoperazone sulbactam sodium was considered to have caused the adverse reactions. After drug withdrawal and supportive treatment, the patient’s platelets gradually returned to normal. Conclusion It is recommended that clinicians be alert to the risk of thrombocytopenia associated with antibiotics such as cefoperazone sulbactam, and monitor platelets during medication in high-risk groups such as the elderly, severe patients, those under a long course of medication, and those with hepatic and renal insufficiency so as to ensure the safety of patients.

Key words: Cefoperazone Sulbactam Sodium, Thrombocytopenia, Adverse Drug Reaction, Antibiotics, Rational Drug Use

中图分类号: